Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gliadel and Metronomic Temozolomide for High Grade Glioma
NCT00548938Phase 2Terminated
- Sponsor
- Methodist Healthcare System of San Antonio
- Start
- Oct 2007
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carmustine, temozolomide in high-grade glioma (HGG), sponsored by Methodist Healthcare System of San Antonio. Started Oct 2007; status: terminated.
02
Drugs
carmustinetemozolomide
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT00548938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00548938.